Novartis CEO Warns US Biotech Curbs on China Could Hamper Drug Development
Vas Narasimhan says proposed Treasury investment limits would hinder technology transfer between US and Chinese operations.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The odds
Each tick is a source publishing on this story · 2 more published before price tracking began
Price data
| Time | Chance of yes |
|---|---|
| now | 21% |
| 19 Nov, 17:45 UTC | 21% |
The story so far
4 publishers have covered this in 5 articles since 18 Nov 2026. South China Morning Post published first, on 18 November at 08:00 UTC; STAT followed 33h 05m later. The most recent article, from Quartz, appeared on 20 November at 14:50 UTC.
Outlets reporting it: Bloomberg Technology (major outlet), South China Morning Post, STAT, Quartz.
One prediction market prices this story:
- By 2030 — the market puts it at 21%, closing 1 Jan 2030. The market resolves to Yes if China's gross domestic product exceeds that of the United States by the year 2030. It resolves to No if China's GDP does not surpass the US total within that timeframe. Readers often mistake the linked news story about rare earth processing for the actual resolution criteria, but only GDP figures determine the outcome.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
How it unfolded
Every source in the order it published, with the odds on By 2030 at that moment. A dash means the source published before we started tracking prices.
- South China Morning PostChina still has ‘catching up to do’ to become biotech powerhouse, JPMorgan says—
- STATSTAT+: Lawmakers want U.S. biotech to outcompete China—
- South China Morning PostUS panel warns of China’s biotech rise, fuelling push to curb ties as Chinese firms unfazed21%
- Bloomberg TechnologyNovartis CEO Says US China Biotech Curbs Risk Drug Development21%
- QuartzNovartis CEO warned U.S. biotech curbs on China could slow drug development21%
- Current odds21%
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novartis CEO Says US China Biotech Curbs Risk Drug Development Bloomberg Technology ·
- Novartis CEO warned U.S. biotech curbs on China could slow drug development Quartz
- US panel warns of China’s biotech rise, fuelling push to curb ties as Chinese firms unfazed South China Morning Post
- STAT+: Lawmakers want U.S. biotech to outcompete China STAT
- China still has ‘catching up to do’ to become biotech powerhouse, JPMorgan says South China Morning Post
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi By 2030 · China overtakes USA’s economy by 2030? 21%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Alert me when the odds move
In this story
- Novartis
- Vas Narasimhan
- US-China Economic and Security Review Commission
- JPMorgan